Contents

31 July 2013
Vol 5, Issue 196

About The Cover

Cover image expansion

ONLINE COVER Fading to Red. Shown are the effects of cancer drug vemurafenib (structure in the center) on signaling through the mTOR pathway in melanoma cells, as demonstrated by Corcoran and co-authors. The upper group of cells comes from a fine needle aspiration of a patient’s melanoma before the initiation of treatment. These cells show bright staining for phospho-S6 (green), a marker of mTOR activity, and a melanoma tumor marker is seen in red. The lower group of cells is from a repeat aspiration of the same tumor 8 days later, after the start of therapy. In these cells, the amount of phospho-S6 is greatly decreased by vemurafenib treatment, which the authors found to be a good prognostic sign for the treated patient. In a related paper, Elkabets and colleagues have also identified an important role for the mTOR pathway in the response of breast cancers to PI3K inhibitors. [CREDIT: S. M. ROTHENBERG/MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER]